Ozekibart meets primary endpoint in chondrosarcoma; BLA submission planned Q2 2026

Inhibrx Biosciences, Inc.

ChonDRAgon study achieved primary endpoint: 52% reduction in risk of progression or death (HR=0.479; p<0.0001); median PFS 5.52 vs 2.66 months.
Disease control rate 54% (ozekibart) vs 27.5% (placebo); benefit consistent across IDH subgroups.
CRC expansion cohort (n=26 evaluable): 23% ORR, 92% disease control rate in heavily pretreated patients.
Ewing sarcoma expansion (n=25 evaluable): 64% ORR, 92% disease control rate; typical standard of care ORR 15-30%.
One fatal hepatotoxicity event early in study; risk mitigated by excluding severe liver impairment and close monitoring; overall hepatic AEs 11.8% vs 4.5%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.